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Cholera, an infectious disease with global impact, is caused by path-
ogenic strains of the bacterium Vibrio cholerae. High-throughput
functional proteomics technologies now offer the opportunity to
investigate all aspects of the proteome, which has led to an
increased demand for comprehensive protein expression clone
resources. Genome-scale reagents for cholera would encourage
comprehensive analyses of immune responses and systems-wide
functional studies that could lead to improved vaccine and thera-
peutic strategies. Here, we report the production of the FLEXGene
clone set for V. cholerae O1 biovar eltor str. N16961: a complete-
genome collection of ORF clones. This collection includes 3,761
sequence-verified clones from 3,887 targeted ORFs (97%). The
ORFs were captured in a recombinational cloning vector to facili-
tate high-throughput transfer of ORF inserts into suitable expres-
sion vectors. To demonstrate its application, 15% of the collec-
tion was transferred into the relevant expression vector and used
to produce a protein microarray by transcribing, translating, and
capturing the proteins in situ on the array surface with 92%
success. In a second application, a method to screen for protein
triggers of Toll-like receptors (TLRs) was developed. We tested in
vitro-synthesized proteins for their ability to stimulate TLR5 in
A549 cells. This approach appropriately identified FlaC, and previ-
ously uncharacterized TLR5 agonist activities. These data suggest
that the genome-scale, fully sequenced ORF collection reported
here will be useful for high-throughput functional proteomic
assays, immune response studies, structure biology, and other
applications.
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The bacterium Vibrio cholerae causes infectious epidemics ofwatery diarrhea that can lead to severe dehydration and death
within a period of hours or days (1–4). Of 200 V. cholerae
serotypes identified thus far, only serogroups 01 and 0139 are
associated with infectious human pandemics. These are endemic to
regions of Asia, Africa, and Latin America, where they continue to
pose a threat to human health (3). Seven pandemics of cholera have
been registered during the past two centuries in endemic areas (5,
6). Epidemic cholera generally has a higher fatality rate, in part
because of the lack of organized response structures. In 1994, an
estimated 12,000 people died in eastern Zaire in 3 weeks. The
case-fatality rate in a single day reached 48%(7) until it was reduced
to 1% by the action of Bangladesh specialists (8).
In addition to its impact on world health, factors including the
high case-mortality rate in epidemics, the ease of spread through
contaminated food and water supplies, the rapid progress of the
disease, the production of a toxin, and the absence of an effective
vaccine have led the U.S. Centers for Disease Control (CDC) to
classify V. cholerae as a category B pathogen, which has placed it on
theNational Institute ofAllergy and InfectiousDiseases priority list
for potential bioterrorism agents (9).
Considerable effort has been devoted to finding an effective
vaccine. Because of the oral–fecal transmission route, recent vac-
cines have been oral, based on inactivated bacteria or live attenu-
ated strains (10, 11). Despite inducing seroconversion, the low level
of protection could not justify their use (12, 13). Nevertheless, some
live attenuated strain vaccines, such as Peru-15, are still being
developed and tested (14).
Infection in endemic areas or in research volunteers confers
protection from reinfection for several years, encouraging the
notion that a vaccine can be found. Protection correlates with a
vibriocidal activity in serum, revealing the importance of the
humoral response to the immunity (15, 16). Although anti-LPS
activity is a component (17), anti-LPS titers alone did not
correlate with protection when familiar contacts with cholera
patients were screened in rural Bangladesh, suggesting the
presence of other protective antibodies in serum (18). The ability
to screen all proteins in the proteome would allow the identifi-
cation of proteins that participate in this immune response and
ultimately lead to vaccination or pharmaceutical treatments.
Recent years have seen the accelerated development of technol-
ogies that study proteins in high throughput. Referred to as
functional proteomics, these methods support the global study of
protein interactions, enzymatic activities, and immune responses.
These applications all rely on the availability of cloned copies of the
protein coding sequences to produce proteins in vivo or in vitro for
these assays. These protein-coding clones must be clonally isolated
and fully sequence-verified to ensure accurate interpretation of the
experiments results. Assembling such clones requires automated
and highly quality-controlled processes, followed by careful se-
quence analysis and evaluation to eliminate any inappropriate
clones (e.g., truncation mutations). We and others have developed
robust pipelines for the production of fully sequence-verified,
genome-scale plasmid collections of protein coding sequences for
a variety of organisms (19–27). In this context, we have initiated the
full length expression-ready gene collection (FLEXGene), which
comprises plasmid clones bearing complete ORFs situated in
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recombinational cloning vectors. These vectors enable the rapid
and efficient in-frame transfer of coding sequences from master
vectors to virtually any protein expression vector in a single con-
servative biochemical step, allowing the transfer of entire libraries
of genes and enabling the broadest possible range of experimen-
tation (19). The FLEXGene effort has included large collections of
human kinases and breast cancer-related genes (26, 28), complete
genome collections for Saccharomyces cerevisiae (22), Yersinia
pestis, and Francisella tularensis (29), as well as a collection for
Pseudomonas aeruginosa (30), which are available at http://
plasmid.hms.harvard.edu, as will be this collection.
The complete genome sequence ofV. choleraeO1biovar eltor str.
N16961 was reported in 2000 (31) with a total of 3,885 predicted
ORFs. Unlike most bacteria, V. cholerae has two chromosomes:
chromosome 1 (2.9 Mb) and chromosome 2 (1.1 Mb) (31), and
chromosomes 1 and 2 contain 2,770 and 1,115 ORFs, respectively.
Approximately 54% of the ORFs are similar to proteins of known
function [58% and 42% for chromosomes 1 and 2, respec-
tively (31)].
Here, we report the assembly of a complete FLEXGene ORF
collection for V. cholerae [supporting information (SI) Table 4]
using a highly automated, quality-controlled clone production
pipeline that includes full sequence verification and analysis of each
clone in the collection. This resource enables a wide variety of
genetic and system-wide assays. Coupled with new technologies
such as proteinmicroarrays, itmight allow the documentation of the
immune responses to, and functional characterization of, each
protein of this pathogen. These results in turn may lead to new
vaccine and therapeutic strategies, and better understanding of the
pathogen biology.
Results
Importing Annotated Sequence Information for a Genome-Scale Set of
3,887 V. cholerae Protein Coding Sequences. We populated a local
database with the start and stop position, as well as the full
sequence, of each coding region from the genome annotations
available for V. choleraeO1 biovar eltor str. N16961 (from here
on referred to as V. cholerae) from both the National Center
for Biotechnology Information (NCBI) and The Institute for
Genome Research (TIGR) (31). Although the annotated
sequence information at TIGR and NCBI was identical for
3,819 predicted V. cholerae ORFs, some differences were
noted (Table 1). We imported the most inclusive set (i.e., the
union of the two annotations; 3,887 ORF sequences) into our
clone production database, FLEXGene (19, 22).
This set includes a small number of ORFs annotated as having
one or more ‘‘authentic frameshifts’’ that predict truncated
polypeptides forV. cholerae compared with correspondingORFs in
other bacteria (Table 2). For each of the 3,887 ORFs represented
in FLEXGene, the following values were included: a unique
FLEXGene sequence identifier; GenBank accession/GI number
for genomic and protein sequence; protein gene symbol and
product name; genome location and coding strand information;
locus tag, which is the systematic gene identifier (i.e., the ‘‘VC’’
number); numerical value for CDS length; percentage GC content;
and nucleotide sequence of the ORF.
Highly Automated Amplification of the V. cholerae ORFeome. We
generated ORF clones via a processing pipeline outlined in Fig. 1
that runs by robotics supported by FLEXGene. Digital images of
agarose gels, robotic colony counts, and OD600 readings of liquid
cultures were stored, enabling retrieval of the clone history for each
clone.
ORF-specific PCR primers were designed to amplify all protein
coding sequences by using genomic DNA as template in one or two
rounds of PCR amplification depending on ORF size (Fig. 1) (22,
25). We normalized all ORFs to start with ATG and replaced stop
codons with TTG (Leu) to allow for the addition of C-terminal
epitope tags.
An overall success of 99% at the PCR step was observed
(3,863 of 3,887 PCRs), with an overrepresentation of clones
2,000 bp among the failures.
Automated Isolation of ORF Clones. The PCR products were cap-
tured in the Gateway vector pDONR221, by using one of two
strategies. ORFs 2,000 bp were captured by using the In-Fusion
cloning protocol because it is more efficient for large clones; ORFs
2,000 bp or smaller were captured by using the standard Gateway
BP capture reaction (Fig. 1) (22). All constructs were transformed
into Escherichia coli and individually plated for robotic single-
colony isolation. Colony counts were recorded, and one isolate per
ORF was collected and used to generate glycerol stocks.
The success rate for small ORFs was 99% (3,610 of 3,638ORFs),
whereas that for large ORFs was 89% (205 of 225). In total, we
successfully obtained clonal glycerol stocks for 3,815 of 3,887ORFs,
a success rate of 97% (Table 3).
DNA Sequence Analysis Reveals High-Quality Capture. To verify the
clones, we fully sequence-verified all of the V. choleraeORF clones
using a process that was managed and analyzed by the automated
clone evaluation software, ACE (32).
Acceptance into the collection required either an exact polypep-
tide match or no more than one amino acid substitution when full,
high-quality sequence coverage was obtained. Clones with inser-
tions, deletions, nonsense mutations (i.e., truncations), or two or
more amino acid differences were rejected. In addition, clones with
nucleotide changes in the att-site sequences were rejected because
of their effect on the recombination reaction.
We encountered difficulty obtaining quality sequence reads from
many clones 500 bp. The sequence traces had clear and inter-
pretable signal peaks that ended abruptly and prematurely at the
same position within the attL sequences, suggesting the formation
of a stem loop structure between the flanking att-site sequences.
Transferring the ORFs to an expression vector, pANT7-cGST,
which has a much shorter attB sequence, enabled full-length
sequencing of these clones.
On a single pass for the genome, we accepted clones for 81.9%
of theORFs (3,125 of 3,815ORFs; Table 2). Of these, 93.2% (2,913
of 3,125) were identical to the reference sequence at the nucleotide
Table 1. Source of protein annotation in genome
Source NCBI TIGR Project target
Total ORF count 3835 3885 3887
Identical ORFs 3819 3819 3819
Same ORF, different annotation 13 13 13 (TIGR version)
ORFs missing from other source 3 53 55*
*VC1131 was not attempted because of size (45 bp).
Table 2. Description of ORFs with reference CDS issues
Reference annotation
ORFs
count
Clone
matching
to ref.
Clone not
matching
to ref.
Authentic frame shift 41 15 26
Authentic point mutation 4 4 0
Reference CDS not multiple of 3,
frame shift not annotated
3 2 1
Reference CDS with in-frame stop,
not annotated
1 1 0
Ambiguous base in genome
sequence
16 2* 14
*Clones not finalized in sequencing.
Rolfs et al. PNAS  March 18, 2008  vol. 105  no. 11  4365
M
IC
RO
BI
O
LO
G
Y
level. Of the accepted but nonidentical clones, 136 had one amino
acid change.
Second-Round Clone Production Leads to >97% Coverage of Pre-
dicted V. cholerae ORFs. A second round of cloning to obtain the
missed cloneswas approached in two steps. Initially, we replated the
frozen transformation reactions that were available for 513 ORFs
of the 762 missing ORFs and sequenced up to four additional
isolates for each (Fig. 1). After this, a de novo cloning round for 382
ORFswas needed to obtain clones that had failed all previous steps.
These included 72 ORFs that failed PCR, capture, or transforma-
tion and 290 ORFs that had failed in sequencing. New cloning
primers were used with the same workflow, except that two
independent clones per target were isolated instead of one, and all
clones were transferred to and sequenced in the expression vector.
Sequence Analysis Summary. In total, 5,772 clones were analyzed,
leading to 4,327 acceptable clones for 3,761 genes (an average of 1.5
analyzed clones per successful ORF). Among redundant clones, the
closest match to the reference sequence was included in the final
collection.
Overall, 92.9% of accepted clones, covering 3,125 of 3,761 ORFs
were a perfect match to the published genome sequence (Table 3).
Silent mutations were detected in 2.1% (90 clones) and 5% (217
ORFs) had one amino acid change. Thus, acceptable clones were
obtained for 3,761 ORFs (97%; complete listing in SI Table 4).
Potential Adjustments to the Genome Annotation. The target se-
quences included 49 ORFs whose official annotated CDS lengths
were not an integer multiple of three (Table 2). These included 41
genes annotated to have an ‘‘authentic frame shift’’, 4 listed to have
an ‘‘authentic point mutation,’’ and 4 with no explanation provided
by either NCBI or TIGR. For 22 of the 49 ORFs, the sequence of
our clone(s) confirmed the presence of a frame shift or stop codon
that would lead to a ‘‘shorter’’ polypeptide in V. cholerae. However,
for 27 of the 49 ORFs (SI Table 5), we did not find the reported
frame shift in any of the isolates we sequenced, suggesting potential
errors in the genome sequence and/or annotation or subtle strains
differences in the genomic template we used.Multiple independent
isolates confirmed the sequence, and the clones were therefore
included.
In addition, 31 of the 123 ORFs that failed sequencing demon-
strated multiple isolates with identical insertion/deletion discrep-
ancies that led to rejection (SI Table 6). This finding may suggest
Fig. 1. Highly automated clone production pipeline. ORFs with an expected
size 2,000 bp were treated differently at PCR, gel analysis, and capture
compared with larger ORFs (Steps 3, 4, and 5). Barcode-labeled plates, blocks,
and dishes were used at all stages, and appropriate results (gel images, colony
counts, OD600, etc.) were stored in the FLEXGene LIMS as indicated, enabling
clone history retrieval.
Table 3. V. cholerae clone production and sequence
validation summary
Item Phase 1 Phase 2 Total
ORF target 3,887 783 3,887
Avg. ORF size 922 889 922
PCR success rate, n (%) 3,863 (99.4) 781 (99.7) 3,885 (99.9)
Capture success rate, n (%) 3,815 (98.1) 781 (99.7) 3,884 (99.9)
Isolate picking 1 per ORF 2–4 per ORF 1.5 per ORF
Clones for sequence
validation
3,815 1,957 5,772
No. of reads 12,823 5,653 18,476
Avg. no. of reads per
clone
3.4  2.6 2.9  3.1 3.2  2.7
Mutation rate 1 of 2,531 1 of 1,002 1 of 1,756
Accepted clones, n (%) 3,125 (81.9) 1,202 (61.4) 4,327 (75.0)
Match perfect with ref.,
n (%)
2,913 (93.2) 1,107 (92.1) 4,020 (92.9)
With silent mutation(s)
only, n (%)
76 (2.4) 14 (1.2) 90 (2.1)
With 1 missense
mutation, n (%)
136 (4.4) 81 (6.7) 217 (5.0)
Rejected clones, n (%) 690 (18.1) 755 (38.6) 1,445 (25.0)
Linker changes 39 25 64
CDS changes
(ins/del/nonsense/mis)
205 274 479
Clones rejected for
other reasons*
446 456 902
Clones needed to
finish a gene
NA 2.9 1.5
Accepted ORFs, n (%) 3,125 (80.4) 682 (87.1) 3,761 (96.8)
Avg., average; ref., reference.
*Other possible reasons for clone rejection include: duplicate clones of fin-
ished gene, no insert was present, insert mismatching, multiple attempts to
resolve discrepancy(ies) failed, or clone failed to grow during or after
validation.
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that the genome sequence may be in error for these ORFs. These
clones were not included in the final collection.
V. cholerae ORF Clone Expression in a Heterologous System and on
Protein Microarrays. As a first functional test of these clones, we
transferred the inserts from 10% of the collection to a bacterial
expression vector and expressed GST fusion proteins in E. coli and
confirmed by Western blot as described (25, 33, 34). Appropriately
sized fusion proteins were detected for 280 (77%) of the tested
ORFs. No signal was detected for 62 ORFs, and aberrantly sized
polypeptides were observed for an additional 34 ORFs (9%) (SI
Fig. 4 and SI Table 7). Overall these results are well within the
previously reported range for other ORF collections (25, 33).
We also tested this set of ORFs for protein expression and
capture on a protein microarray method called NAPPA (nucleic
acid programmable protein array), previously developed in our
laboratory. Instead of the standard process of printing purified
proteins onto a microarray surface, NAPPA entails printing full-
length cDNAs encoding the respective proteins along with a
capture antibody. At the time of assay, this ‘‘cDNA’’ array is
converted into a protein array by transcribing and translating the
proteins in situ. The nascent proteins are captured to the array
surface by capture antibody directed at a glutathione-S-transferase
(GST) tag added to the carboxyl end of each protein by the
expression vector. This obviates some common problems of pro-
tein-spotted protein microarrays, such as the challenges inherent in
purifying the proteins and the short shelf life of many purified
proteins (35). The C-terminal location of the tag ensures that
proteins are fully translated and can potentially be confirmed with
a different anti-GST antibody. Here, we printed various concen-
trations of purified GST protein to allow for semiquantitative
assessment of the yield of captured proteins. Protein was readily
detected for 319 of the 345 clones tested (92%) (Fig. 2). For the 26
failed plasmids, 23 did not display sufficient DNA on the array
surface as measured by picogreen binding, whereas 3 failed protein
expression evenwhen sufficientDNAwas observed (SITable 7).As
expected, control features without DNA or purified GST protein
did not show measurable reactivity.
V. cholerae Fusion Proteins Are Active in Biological Assays.As a proof
for biological activity, we tested in an assay designed to discover
Toll-like receptor (TLR) agonists whether in vitro-produced C-
terminal GST-tagged V. cholerae proteins were biologically active.
To address this question, we used A549 NF-B reporter cells in
which a luciferase gene is transcribed under the control of an
NF-B-responsive promoter. A549 cells express endogenously
TLR5, and thus, show luciferase expression as response after being
challenged with bacterial flagellins (36–39). As shown in Fig. 3a,
high-level induction of NF-B was detected in A549 cells exposed
to in vitro transcription/translation extracts that contained plasmids
coding for GST fusion proteins to the V. cholerae flagellins FlaD
and FlaC (Fig. 3, columns 1 and 2) in an extract-dependentmanner.
In addition, NF-B-dependent transcriptional activation was also
detected in cells treatedwith aGST-fused outermembrane protein,
OmpA (Fig. 3A, column 4). Extracts were positive when these
proteins were synthesized either alone or in combination with five
other V. cholerae proteins. Two control mixtures, either only
extracts or only plasmid DNA, did not stimulate NF-B activation.
GST fusion protein synthesis was confirmed by Western blot
analysis using an anti-GST antibody (Fig. 3B). VCA0679 (periplas-
mic nitrate reductase), naturally having a heme group as cofactor,
was not produced (lane 3), and VC2213 (OmpA) was detected at
abnormally high molecular weight (lane 4), potentially because of
forming stable multimers.
To further confirm the feasibility to identify innate immunity
candidates, we used the A549 activation screen to examine a
subset of the ORFeome library consisting of 552 proteins
expressed in 94 pools of five or six different ORFs each (SI Table
8). We found three pools with a positive response in this screen,
with two of these pools containing plasmids that were known or
Fig. 2. Representative protein microarray (NAPPA) results of V. cholerae
proteins. ORFs (n  346) were transferred and arrayed as plasmid DNA onto
protein microarrays, and expression on the array was tested. (A and B) The
DNA-to-protein relationships. (Upper) Picogreen detection of DNA. (Lower)
The corresponding GST protein. (A) Controls spotted onto the array; on the
left and right are 8 features for plasmids that do not encode protein, and in
the center are 12 features of purified GST protein. (B) A comparison of 32 V.
cholerae ORFs; all ORFs display DNA, but variation in ORF-specific protein
expression/capture. (C) Examples for the entire set of controls and ORFs tested
on NAPPA; left array, DNA detection by picogreen staining; right array,
protein expression/capture by anti-GST antibody.
Fig. 3. V. cholerae proteins expressed in vitro are active in biological assays.
(A) Six different proteins were produced alone or together as a pool. After in
vitroprotein production, 10l of each RRL mixture and its serial dilutions were
added to treat A549 reporter cells for 4 h. Luciferase-based NF-B activation
was shown in the bottom. Squares shown in red indicate positive NF-B
activation. FlaD, flagellin D; FlaC, Flagellin C; NAR, nitrate reductase; OmpA,
outer membrane A; FNR, anaerobic transcriptional activator; TR Fac, transcrip-
tion factor. (B) Western blot analysis of in vitro-synthesized proteins.
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predicted to be TLR5 agonists, FlaA (flagellain core protein A,
VC2188), and FlaC (VC2187), respectively. However, pool G6
was entirely made up of plasmids coding for proteins previously
not known to be either activators of the innate immune system
or agonist of TLR5. Repeated screening confirmed that pool G6
encodes proteins that exhibit TLR5 stimulation, and further
analysis of this pool to identify and characterize the relevant
ORF (S.S.Y., A. Thanawastien, W.R.M., J.L., and J.M., unpub-
lished results). In conclusion, the V. cholerae FLEXGene library
can be used to efficiently discover proteins with new biological
activities of interest.
Discussion
It has been almost a century since V. cholerae was identified as the
causative agent of cholera, yet the disease remains a leading cause
of death in tropical countries, and new endemic outbreaks continue
to occur with some frequency. Prevention of cholera suffers from
the lack of an effective and affordable vaccine, despite a variety of
efforts to produce one from heat-treated, attenuated and non-
pathogenic V. cholerae strains. To open up possible routes to
vaccine and therapeutics development, we used a highly automated
cloning pipeline and performed end-to-end sequencing to produce
a complete clone collection that covers protein coding regions in the
V. cholerae genome. Importantly, this collection will make it pos-
sible to perform a direct analysis of each individual V. cholerae
protein’s contribution to the immune responses in previously in-
fected subjects.
We encountered several instructive challenges during the cloning
process. We noted that the sequence analysis of short ORFs (500
bp) is particularly problematic using a vector containing attL
sequences flanking the insert. The most likely explanation for this
was the nature of the attL1 and L2 sequences, which contain nearly
identical extended direct repeats (90 of 94 nt) at both ends of the
insert that may form heat-stabile secondary structures. Transfer of
the inserts to expression vectors containing attB sequences (60 nt
shorter) rectified this problem.
We also encountered several potential errors in the published
genome sequence or its annotation, including: a set of genes that did
not display authentic frame shifts annotated in the genome, and
conversely, a small number of ORF sequences for which multiple
independent isolates exhibited identical frame shift-causing trun-
cation mutations. The sequence data reported here should help to
update the genome annotation for V. cholerae.
As shown for a randomly selected set of clones, use of the clones
for high-throughput protein production in E. coli resulted in a
success ratewell within a published range for other clone collections
(25, 33, 34). Most proteins (242 ORFs) were expressed by both
protein expression methods. In general, the NAPPA method was
more successful, achieving a 99% success rate for features that had
adequate DNA. In the future, the protein microarrays may prove
useful for clinical proteomics applications such as serum screens to
identify vaccine candidates, studies to identify immune biomarkers
of infection, and as tools to track the success of response to vaccines.
In addition, we used this ORF collection in a biological screening
approach to identify Toll-like receptor agonists. We initially tested
the feasibility with known agonists of TLR5 and tested a subset of
otherORFs in pools of five to six ORFs for TLR5-mediatedNF-B
stimulation with a reporter gene assay. This approach was validated
by confirming FlaC and FlaA activity either alone or by using this
pooling strategy and further led to a promising finding of an activity
in one of the pools in this screen. Although this will need further
analysis, this pilot screen shows the potential of a well annotated
ORF collection for a microorganism in the identification of bio-
medically relevant proteins heretofore not identified. In this regard,
it is interesting to note that adverse symptoms experienced by
human subjects ingesting two attenuated cholera vaccines were
reported to be mitigated by introduction of mutations that blocked
flagella expression (40). Thus, the screening of FLEXgene libraries
for TLR agonists can potentially identify bacterial ligands whose
deletion from live attenuated vaccines will render them safer and
less prone to induction of adverse side effects. A complete screen
of the entire V. cholerae proteome remains to be completed.
These preliminary results for protein expression and functional
application, together with the high-quality standard applied to the
collection, suggest that the plasmid clone resource created here will
be useful for a wide variety of assay types and experimental
approaches to the study of V. cholerae, including detailed studies of
the immune responses in infected individuals and genetic screens to
study the pathways of essential genes.
Information about these clones can be found at our own
center, PlasmID (http://plasmid.med.harvard.edu/PLASMID/),
and the Resource Center for Biodefense Proteomics Research
(http://www.proteomicsresource.org/) Any or all of the clones
here can be obtained from PlasmID (http://plasmid.med.
harvard.edu/PLASMID/) and the Pathogen Functional Genom-
ics Resource Center (PFGRC) (http://pfgrc.tigr.org/).
Materials and Methods
Import of Annotated Genome Information for V. cholerae. Protein-coding
regions that were annotated based on the genome sequence of V. cholerae
N16961 ‘‘El tor’’ were downloaded from NCBI and TIGR (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?dbgenomeprj&cmdRetrieve&dopt
Overview&listuids36 and http://www.tigr.org/tigr-scripts/CMR2/
GenomePage3.spl?databasegvc). A text parser was developed in-house to
extract sequences and annotation of predicted ORFs downloaded from NCBI
or TIGR.
ORF-Specific Primer Design and Strategic 96-Well Plate Organization. ORF
sequences were imported into the FLEXGene LIMS (http://flex.med.harvard.edu/
FLEX/), and primer sequences were designed by using a nearest-neighbor algo-
rithm, with primers adjusted to achieve a Tm  58°C. Moreover, start codon
sequences were normalized to ATG (Met) and natural stop codons were replaced
with TTG (Leu) to allow for 3 tags. The primers also included fixed sequences that
correspond to partial att sequences that flank the ORF in the resultant plasmid
clones (22).
PCR amplicons of different sizes were treated differently in two groups: those
2,000 bp and those smaller. Within each group, the ORFs were arranged on
96-well production plates in a saw-tooth pattern to enable rapid visual detection
of ORFs that failed to amplify or that amplified the wrong size. This also reduced
cross-contamination during gel isolation. Oligonucleotide primers were pur-
chased from Integrated DNA Technologies as 50 M normalized solutions and
diluted to 0.083 M before use in PCRs.
PCR and Capture in the Entry Vector, pDONR221. PCR was performed in
barcode-labeled, 96-well plates and verified by images of agarose gel electro-
phoresis that were uploaded into FLEXGene. PCR products representing ORFs
2,000 bp were isolated from the gel and purified before capture in linearized
entry vector as described (22).
PCR products representing smaller ORFs were captured by using the BP Clo-
nase-basedcapturemethod(Invitrogen), followingprotocolsdescribed in ref.25.
Clonal Isolation and Production of Glycerol Stocks. All products were trans-
formed into DH5 T1-resistant E. coli, plated to 48-sector LB/agar dishes. A
customized Megapix robot (Genetix) was used to count colonies, capture an
image, isolate the indicated number of single colonies from each sector of the
agar dish, and inoculate the colony into 1 ml of growth media (LB/antibiotic).
Overnight culture growth at 37°C was verified by OD600 measurement, and
aliquots were stored at80°C as 15% glycerol stocks.
Plasmid DNA Preparation, Sequencing, and Analysis. Plasmid DNA was prepared
as described (30). All DNA sequencing was performed at the Dana–Farber/
Harvard Cancer Center DNA Resource Core by using standard M13 or gene-
specific primers (sequences available upon request).
For analysis, sequence data and annotated ORF reference sequences were
imported into the Automated Clone Evaluation (ACE) suite of software tools (32).
ACE was then used to perform all DNA sequence and clone evaluation steps,
including sequence quality assessment, contig assembly, identification of cover-
age gaps, design of oligonucleotide primers for internal sequencing, conceptual
translation of experimentally determined sequence contigs, and automated
acceptance and rejection of individual clone samples based on user-defined rules
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for minimal and maximally acceptable differences between the experimental
and reference sequences at the nucleotide and amino acid levels.
Transfer of ORFs from the Entry Vector into E. coli Expression Vectors. Transfer
reactions from pDONR221 into either pANT7-cGST (35) or pDEST-GST (33) were
done with LR kits from Invitrogen, following the manufacturer’s instructions and
as described (22, 25, 30). Transfer reactions were transformed into a T1-resistant
E. coliDH5host strain and plated onto LB-agar/ampicillin 48-well grid plates for
single colony selection. Individual isolates were inoculated by using robotics as
described above. Glycerol stocks were generated and stored for each isolate.
Induction of Protein Expression and GST Immunoblotting. Glycerol stock cultures
of expression clones in pDEST-GST were spotted on agar plates with appropriate
antibiotic selection to generate even growth conditions, incubated at 37°C, and
usedto inoculate liquidcultures in96-wellplates.Aftergrowthovernightat37°C,
liquid cultures were diluted 1:500 and regrown until an OD600 of 0.6–0.8 was
reached. Protein expression was induced by addition of 1 mM IPTG (final con-
centration), and cultures were incubated for 4 h at room temperature with
constant shaking. One hundred microliters of each culture was centrifuged, and
cell pellets were dissolved in 20 l of SDS/PAGE sample buffer, followed by
separation on precast 10% Criterion gels (Bio-Rad). Immunoblot analysis using
monoclonal anti-GST antiserum was performed as described (35).
Protein Microarray (NAPPA) Synthesis and Expression. Expression constructs
were grown in appropriate media (LB-amp) and DNA harvested and purified and
modified before the array as described (35). Modified DNA together with poly-
clonal anti-GST antibody (Amersham) were applied to presilanized glass slides
with a commercial DNA microarray robot (Genetix), followed by incubation with
PicoGreen (1:600; Molecular Probes) to confirm the presence of DNA at each
feature or with the TNT system (T7; Promega) for in situ protein synthesis on the
glass arrays. All proteins were detected by using a monoclonal anti-GST antibody
(Cell Signaling Technology), ensuring detection of full-length protein.
In Vitro Protein Synthesis by Rabbit Reticulocyte Lysate Mixture. In vitro protein
synthesis was performed by using the TnT coupled reticulocyte lysate system kit
(Promega) followingthemanufacturer’s instructions.Thereactioncontained100
ng of plasmid DNA (total) and 24 l of rabbit reticulocyte lysate mix.
A549 Cell Culture and Luciferase Assay. Human alveolar epithelial cells, A549,
stably transfected with a luciferase-based NF-B reporter construct (Panomics)
were grown in DMEM containing 10% FBS, 2 mM L-Glutamine and 100 g/ml
hygromycin at 37°C in a humidified 5% CO2 incubator. To measure NF-B acti-
vation, 2  104 cells were seeded in 96-well plates and cultured overnight. The
next day, cells were treated with either in vitro-synthesized proteins or serial
dilutions of such for 4 h. Luciferase activity was measured by using Bright-Glo
luciferase assay kit (Promega) in a SpectraFluor plus plate reader (Tecan).
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